Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Leases (2019 - 2025)

CytomX Therapeutics (CTMX) has disclosed Current Leases for 7 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases rose 11.9% year-over-year to $5.6 million, compared with a TTM value of $5.6 million through Sep 2025, up 11.9%, and an annual FY2024 reading of $5.1 million, up 12.12% over the prior year.
  • Current Leases was $5.6 million for Q3 2025 at CytomX Therapeutics, up from $5.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $5.6 million in Q3 2025 and bottomed at $3.6 million in Q4 2021.
  • Average Current Leases over 5 years is $4.6 million, with a median of $4.5 million recorded in 2023.
  • The sharpest move saw Current Leases grew 12.82% in 2022, then increased 11.9% in 2025.
  • Year by year, Current Leases stood at $3.6 million in 2021, then increased by 12.82% to $4.1 million in 2022, then grew by 12.42% to $4.6 million in 2023, then rose by 12.12% to $5.1 million in 2024, then increased by 8.77% to $5.6 million in 2025.
  • Business Quant data shows Current Leases for CTMX at $5.6 million in Q3 2025, $5.4 million in Q2 2025, and $5.3 million in Q1 2025.